Interleukin Genetics' PerioPredict genetic risk test will now be covered by New England's Comprehensive Benefit Administrators' (CBA) Freedom Dental Plan after an April 21 agreement between Interleukin and Reimbursement Specialists, a CBA company.
PerioPredict produces genetic data that can lower a patient's systemic inflammatory burden to reduce the risk of periodontitis and other chronic diseases, according to the company.
"We are thrilled to add an innovative new benefit that uses genetic testing to drive personalized care as a component to our Freedom Dental Plan," stated Mike McKenna, president and CEO of CBA, in a press release. "This unique test will differentiate our plan, providing added value for current and prospective customers."
